# STF-62247 and pimozide induce autophagy and autophagic cell death in mouse embryonic fibroblasts

Maximilian N. Kinzler<sup>1,3§</sup>, Svenja Zielke<sup>1§</sup>, Simon Kardo<sup>1</sup>, Nina Meyer<sup>2</sup>, Donat Kögel<sup>2</sup>, Sjoerd J. L. van Wijk<sup>\*1</sup>, Simone Fulda #<sup>\*1,3,4</sup>

<sup>1</sup>Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany <sup>2</sup>Experimental Neurosurgery, Goethe-University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany <sup>3</sup>German Cancer Consortium (DKTK), Partner Site Frankfurt, Germany <sup>4</sup>German Cancer Research Center (DKFZ), Heidelberg, Germany

§ shared first authorship, \* shared senior authorship, # corresponding author

Pimozide decreases the levels of the mitochondrial proteins Mfn2 and COXIV in *Atg5+/+* and *Atg7+/+* cells . STF-26647 decreases levels of COXIV, but not of Mfn2 in *Atg5+/+* cells, whereas STF-26647 does not decrease levels of COXIV or Mfn2 in Atg7+/+ cells. ATG5<sup>+/+</sup> and ATG7<sup>+/+</sup> MEFs were transiently transfected with mCherry-Parkin followed by treatment with 10  $\mu$ M FCCP, 10  $\mu$ M pimozide or 10  $\mu$ M STF-62247 for the indicated time points followed by Western blotting with vinculin as loading control. Uncropped blots are shown in Suppl. Fig. 13. Mfn2 = mitofusin-2

			م mCh	ATG7+/ erry-P	+ Parkin				mCh	ATG5+ erry-F	/+ Parkin	
FCCP [h]	0	8	24	0	0	0	0		0	0	0	
PIMO [h]	0	0	0	8	24	0	0		0	0	0	
STF [h]	0	0	0	0	0	8	24		0	8	24	
Mfn2	1	- Marrie	-	1	-	1	-	- 100 kDa	-	-	-	— 100 kDa
								<b></b> 70 kDa				— 70 kDa
mCherry- Parkin	-	-		-		-	-	— 100 kDa	-			<del>—</del> 100 kDa
LC3B	-	-		-	=	=	=	— 15 kDa	-	1	11	— 15 kDa
cox-ıv [	-	3	-	-		-	5	— 15 kDa	1 18	1 35		— 15 kDa
Vinculin				-		-	_	100 kDa 70 kDa			-	— 100 kDa — 70 kDa



55 kDa

- 35 kDa 25 kDa

> 15 kDa 10 kDa 35 kDa



FK2 (total ubiquitin)

GAPDH



GAPDH

FK2

35 kDa

#### Figure 1A/B: original blots in different exposures

#### Suppl. Fig. 3

#### (1) Vinculin, ATG7, LC3B



(3) Vinculin, ATG7, LC3B



(2) Vinculin, ATG7, LC3B













# Figure 1C: original blots in different exposures



Marked samples are part of the present study.

#### (1) Vinculin



#### (2) Vinculin



## (3) LC3B



## (5) LC3B



#### (4) LC3B



Marked samples are part of the present study.

## (1) Vinculin



## (2) Vinculin



# (3) LC3B

	Fig. 3 C.			Fig. 3.A			Fig. 3.D										
1.5		-	-	-	-	-	1				1	-	-	-	-		
		-		-		-	-	-	-	-	-		-		-		13
						•	-			3				•		•	13

## (4) Vinculin



#### (5) LC3B



(1) GAPDH

(2) GAPDH





## (3) RFP





(6) ATG5





# (4) RFP, ATG5



#### Figure 7C: original blots in different exposures

Marked samples are part of the present study. Lysates were loaded onto two different gels (#1 and #2). #1 and #2 indicates which proteins were detected from the respective gel.

(1) GAPDH (#1), GAPDH (#2)



## (2) Mitofusin-2 (#1), GAPDH (#1), GAPDH (#2)



## Figure 7C: original blots in different exposures

Marked samples are part of the present study. Lysates were loaded onto two different gels (#1 and #2). #1 and #2 indicates which proteins were detected from the respective gel.

(3) Mitofusin-2 (#1), GAPDH (#1), GAPDH (#2)



#### Figure 7C: original blots in different exposures

Marked samples are part of the present study. Lysates were loaded onto two different gels (#1 and #2). #1 and #2 indicates which proteins were detected from the respective gel.

(4) COX-IV (#1)





(7) COX-IV (#1), RFP (#2), ATG5 (#2)



Suppl. Fig. 12

## Suppl. Fig. 1: original blots in different exposures

Marked samples are part of the present study.

## (1) Mitofusin-2



(2) mCherry-Parkin



(3) COXIV



(4) LC3B



(5) Vinculin

				1
ATG5+/+		• 9	ATG7+/+	Vinc.
 				- 130
	·			- 1

# (1) FK2 (total ubiquitin)



(2) GAPDH

